Program

Wednesday 26/04/2023

18:00 Registration

Session 9th NovAliX Conference - DAY 1

19:00 Opening & Welcome Address by NovAliX Conferences Chairman

Dr Jean-Paul RENAUD (URANIA THERAPEUTICS, Ostwald, France)

SESSION 1: EMERGING TECHNOLOGIES - NEW BIOPHYSICAL APPROACHES FOR MEASURING MOLECULAR INTERACTIONS

Session Chair

Dr Chaohong SUN

(ABBVIE, North Chicago, United States)

19:10 Kinetic Characterization of Ligand and Antibody Binding to Cell Surface Expressed CCRL2 Using Surface Plasmon Resonance Microscopy (SPRM) (IL01)

Dr Jonathan BROOKS (PFIZER, Cambridge, United States)

19:40 Single-Molecule Analysis of Drug-Target Interactions Using a Molecular Forceps (OC01 - virtual presentation)

Prof. Terence STRICK (ECOLE NORMALE SUPÉRIEURE, Paris, France)

19:55 Exhibitor Short Presentation

Single Molecule Microscopy-Based Platform for Biophysical Characterization of Drug Candidates (ESP01)

Dr Tim P. KAMINSKI

(INSINGULO SOLUTIONS AB, Mölndal, Sweden)

20:05 NMR Reporter Assays for the Quantification of Weak-Affinity Receptor-Ligand Interactions (OC02)

Dr Reto WALSER

(ASTEX PHARMACEUTICALS, Cambridge, United Kingdom)

20:20 Exhibitor Short Presentation

heliX® Biosensors: Measuring Interactions from Small Molecules to Cells (ESP02)

Dr Antonio DI MECO (DYNAMIC BIOSENSORS GMBH, Woburn, United States) (SANOFI-AVENTIS DEUTSCHLAND GMBH)

20:30 High-Throughput Protein Analysis and Binding Assays Enabled by IR-MALDESI-MS (IL02)

Dr Nathaniel ELSEN

(ABBVIE INC., North Chicago, United States)

21:00

Coffee Break & Exhibition on-site

SESSION 2: COVALENT DRUG DISCOVERY

Session Chair

Dr Daniel WYSS

(MERCK & CO., INC., Morristown, United States)

21:30 Developing Covalent Small Molecules for Protein Targets from Kinases to Transcription Factors (IL03)

Dr Tinghu ZHANG

(STANFORD, Stanford, United States)

22:00 Covalent Screening and Hit Characterization Methods for Efficient Covalent Drug Discovery (OC03)

Dr Mela MULVIHILL

(GENENTECH, INC., South San Francisco, United States)

22:15 In-Cell Covalent Inhibitors Discovery (IL04)

Dr Brent MARTIN

(SCORPION THERAPEUTICS, Boston, United States)

Program

22:45 Exhibitor Short Presentation

Biophysical and Structural Biology Methods Enable Fragment-Based Covalent Ligand Discovery (ESP03)

Dr Tobias DEIMLING

(CRELUX, A WUXI APPTEC COMPANY, Martinsried, Germany)

22:55 Discovery of the KRAS G12C Covalent Drug Adagrasib and Beyond (OC04)

Dr Robin GUNN

(MIRATI THERAPEUTICS, San Diego, United States)

23:10 Exhibitor Short Presentation

NovAliX: Drug Discovery from Stand-Alone to Integrated Projects (ESP04)

Dr Jonathan SETHNA (NOVALIX, Philadelphia, United States)

KEYNOTE LECTURE

23:20 Sequence-Based Design of RNA-Targeted Small Molecules (KL01)

Prof. Matthew DISNEY

(UF SCRIPPS, Jupiter, United States)

00:20

Welcome Reception for on-site participants

Sponsored by ALPX

01:30 End of the Day

Program

Thursday 27/04/2023

14:00 Registration

Session 9th NovAliX Conference - DAY 2

SESSION 3: HYBRID METHODS AND TECHNIQUE COMBINATIONS

Session Chair

Dr Holly SOUTTER

(BROAD INSTITUTE, Cambridge, United States)

15:00 Leishmania Translation Initiation Factor IF4E: a Potential Target for Antiparasitic Drug Development (IL05)

Dr Mélissa LÉGER-ABRAHAM

(BLAVATNIK INSTITUTE | HARVARD MEDICAL SCHOOL, Boston, United States)

15:30 Drug Discovery for the Oncogenic Protein KRAS on a Model Membrane (OC05)

Dr Fenneke KLEINJAN (UHN, Toronto, Canada)

15:45 HDX-MS Use as a Complementary Technique to X-ray Crystallography and Cryo-EM to Better Understand

Small Molecule Binding Events (OC06)

Dr Fabrice CIESIELSKI (NOVALIX, Illkirch, France)

16:05

Coffee Break & Exhibition on-site

16:35 Integration of Biophysics and Simulation to Drive Drug Discovery (IL06)

Dr Holly SOUTTER

(BROAD INSTITUTE, Cambridge, United States)

17:05 Biophysical Characterization of Allosteric Cooperativity in PRMT5 (OC07)

Prof. Till MAURER

(IDEAYA BIOSCIENCES, South San Francisco, United States)

17:20 Exhibitor Short Presentation

Integrated Use of Biophysics to Improve Data and Decision Quality in Drug Discovery (ESP05)

Dr Stoyan MILEV

(MALVERN PANALYTICAL INC., Westborough, United States)

17:30 Identification and Characterization of Modulators of DEAH-Box Helicase DHX9 (OC08)

Dr Ann BORIACK-SJODIN

(ACCENT THERAPEUTICS, Lexington, United States)

KEYNOTE LECTURE

17:45 How Ligand-Binding Biophysics can Advance a Small-Molecule Neuroscience Portfolio (KL02)

Dr Laura SILVIAN

(BIOGEN, Cambridge, United States)

18:45

Lunch, Networking & Exhibition on-site

19:45

In-person delegates: Poster Session 1

Virtual delegates: Meet & Greet discussion with Exhibitors

SESSION 4: BIOPHYSICAL ASSAYS FOR PROTACS AND MOLECULAR GLUES

Session Chair

Dr Claudio CIFERRI

(GENENTECH, South San Francisco, United States)

Program

20:30 An Integrated Biophysical Approach to Discover Ligands for a Novel E3 Ligase (IL07)

Dr Nichole O'CONNELL

(KYMERA THERAPEUTICS, Watertown, United States)

21:00 Exhibitor Short Presentation

Cube Biotech Combines Seamless Gene-to-CryoEM Structure Service with its Detergent-Free Membrane Protein Stabilization Platform Technology Native Nanodiscs (ESP06)

Dr Barbara MAERTENS

(CUBE BIOTECH, Monheim, Germany)

21:10 Targeted MDM2 Degradation Reveals a new Vulnerability for P53-Inactivated Triple Negative Breast Cancer (OC09)

Dr Joseph SALVINO

(THE WISTAR INSTITUTE, Philadelphia, United States)

21:25

Coffee Break & Exhibition on-site

21:55 Capturing the Flexibility of CRBN Protacs with Cryo-EM (OC10)

Dr Daniel PETER

(BOEHRINGER INGELHEIM, Vienna, Austria)

22:10 Exhibitor Short Presentation

How Cryo-EM is Transforming Drug Discovery (ESP07)

Dr Zuben BROWN

(THERMO FISHER SCIENTIFIC, Hillsboro, United States)

22:20 A Covalent BTK Ternary Complex Compatible with Targeted Protein Degradation (IL08)

Dr Matthew CALABRESE (PFIZER, Groton, United States)

22:50 Round Table set-up

22:55 Round Table Discussion:

Biophysics and Structural Biology Studies to Assist the Development of PROTACs, Molecular Glues and Beyond

Moderated by

Dr Katarzyna MARCINKIEWICZ

(NATURE COMMUNICATIONS, New York, NY, United States)

23:40

In-person delegates: Poster Session 2

Virtual delegates: Meet & Greet discussion with Exhibitors

00:30 End of the Day

01:00

Conference Dinner on-site (subject to prior registration)

Program

Friday 28/04/2023

Session 9th NovAliX Conference - DAY 3

SESSION 5: SMALL MOLECULES TARGETING RNA / UNDERSTANDING SMALL-MOLECULE SELECTIVITY TOWARDS RNA

Session Chair

Dr MariJean EGGEN

(ELI LILLY, Indianapolis, United States)

15:00 Exploring the Undiscovered Country of RNA as a Drug target — Finding Bioactive Ligands against XIST RNA with Affinity-selection MS Screening (IL09)

Dr Elliott B. NICKBARG

(MERCK & CO., INC., Boston, United States)

15:30 Exhibitor Short Presentation

Atropisomers in Kinase Inhibitors (ESP08)

Mr Branden LEE

(BIRDOTECH, San Diego, United States)

15:40 Exhibitor Short Presentation

Developments in Sample Preparation and Handling Technology for Crystallography and Cryo-EM (ESP09)

Ms Joyce FRANK

(MITEGEN, Ithaca, United States)

15:50

Coffee Break & Exhibition on-site

16:20 Exhibitor Short Presentation

Automated Protein Crystallography for Structure Determination and Expert Small-Molecule Screening (ESP10)

Dr Andrea PICA

(ALPX, Grenoble, France)

16:30 A Structure-based Approach to Discovering RNA-targeted Small Molecules (IL10)

Dr Elena MENICHELLI

(ARRAKIS THERAPEUTICS, Waltham, United States)

KEYNOTE LECTURE

17:00 Reimagining Druggability using Chemoproteomic Platforms (KL03)

Prof. Daniel NOMURA

(UC BERKELEY, Berkeley, United States)

18:00 Poster Prizes & Closing Remarks

18:10 Departure